PBAC's latest decision on Thalidomide: Recommended with restriction (2009). Considered for Treatment of patients newly diagnosed with multiple myeloma who are ineligible for treatment with high dose chemotherapy or a stem cell transplant; and treatment of a patient newly diagnosed with multiple myeloma.
PBAC outcome
Recommended with restriction
2009
ICER (AUD/QALY)
$45k/QALY
Range: $15k/QALY–$45k/QALY
Submissions
1
first 2009
Submissions
1
2009 → 2009
Eligible population
patients newly diagnosed with multiple myeloma who are ineligible for treatment with high dose chemotherapy or a stem cell transplant; and patients newly diagnosed with multiple myeloma
Therapy area
Oncology
Evidence base
RCT
Primary endpoint
OS, PFS, Response rate (CR+VGPR+PR)
Key trials
Facon et al (2007), Hulin et al (2007), Waage et al (2007), Rajkumar et al (2006), Lokhorst et al (2008), Barlogie et al (2006)
Comparator
For ineligible HDC/SCT patients: melphalan and prednisone alone (MP). For eligible HDC/SCT patients: vincristine, adriamycin and dexamethasone (VAD)